Natural history of t(11;14) multiple myeloma.

MedStar author(s):
Citation: Leukemia. 32(1):131-138, 2018 01.PMID: 28655925Institution: MedStar Washington Hospital CenterDepartment: Medicine/Internal MedicineForm of publication: Journal ArticleMedline article type(s): Journal ArticleSubject headings: *Chromosomes, Human/ge [Genetics] | *Multiple Myeloma/ge [Genetics] | *Multiple Myeloma/pa [Pathology] | Adult | Aged | Aged, 80 and over | Chromosome Aberrations | Female | Humans | In Situ Hybridization, Fluorescence/mt [Methods] | Male | Middle Aged | Neoplasm Staging/mt [Methods] | Prognosis | Translocation, Genetic/ge [Genetics] | Young AdultYear: 2018ISSN:
  • 0887-6924
Name of journal: LeukemiaAbstract: Translocation (11;14) on interphase FISH in plasma cells is regarded as a standard risk prognostic marker in multiple myeloma (MM) based on studies conducted before introduction of current therapies. We identified 365 patients with t(11;14), and 730 matched controls:132 patients with non-(11;14) translocations and 598 with no chromosomal translocation. The median progression-free survival (PFS) for the three groups were 23.0 (95% CI, 20.8-27.6), 19.0 (95% CI, 15.8-22.7) and 28.3 (95% CI, 25.7-30.6) months respectively [P<0.01]. The median overall survival (OS) for t(11;14), non-(11;14) translocation and no-translocation groups were 74.4 (95% CI, 64.8-89.3), 49.8 (95% CI, 40.0-60.6) and 103.6 (95% CI, 85.2-112.3) months respectively [P<0.01]. Excluding those with 17p abnormality, the median OS in the three groups were 81.7 (95% CI, 67.0-90.7), 58.2 (95% CI, 47.0-76.4) and 108.3 (95% CI, 92.4-140.1) months respectively [p P<0.01]. The above relationship held true in patients with age <65 years, ISS I/II stage or those who received novel agent-based induction. Advanced age (hazard ratio [HR]: 1.98), 17p abnormality (HR: 2.2) and ISS III stage (HR: 1.59) at diagnosis predicted reduced OS in patients with t(11;14). These results suggest that outcomes of t(11;14) MM is inferior to other standard risk patients.Leukemia accepted article preview online, 27 June 2017. doi:10.1038/leu.2017.204.All authors: Buadi FK, Dingli D, Dispenzieri A, Fonder AL, Gertz MA, Go RS, Gonsalves WI, Hayman SR, Hobbs MA, Hwa YL, Kapoor P, Kourelis TV, Kumar SK, Kyle RA, Lacy MQ, Lakshman A, Leung N, Lin Y, Lust JA, Moustafa MA, Rajkumar SV, Russell SJ, Zeldenrust SRFiscal year: FY2018Fiscal year of original publication: FY2017Digital Object Identifier: Date added to catalog: 2017-07-10
Holdings
Item type Current library Collection Call number Status Date due Barcode
Journal Article MedStar Authors Catalog Article 28655925 Available 28655925

Translocation (11;14) on interphase FISH in plasma cells is regarded as a standard risk prognostic marker in multiple myeloma (MM) based on studies conducted before introduction of current therapies. We identified 365 patients with t(11;14), and 730 matched controls:132 patients with non-(11;14) translocations and 598 with no chromosomal translocation. The median progression-free survival (PFS) for the three groups were 23.0 (95% CI, 20.8-27.6), 19.0 (95% CI, 15.8-22.7) and 28.3 (95% CI, 25.7-30.6) months respectively [P<0.01]. The median overall survival (OS) for t(11;14), non-(11;14) translocation and no-translocation groups were 74.4 (95% CI, 64.8-89.3), 49.8 (95% CI, 40.0-60.6) and 103.6 (95% CI, 85.2-112.3) months respectively [P<0.01]. Excluding those with 17p abnormality, the median OS in the three groups were 81.7 (95% CI, 67.0-90.7), 58.2 (95% CI, 47.0-76.4) and 108.3 (95% CI, 92.4-140.1) months respectively [p P<0.01]. The above relationship held true in patients with age <65 years, ISS I/II stage or those who received novel agent-based induction. Advanced age (hazard ratio [HR]: 1.98), 17p abnormality (HR: 2.2) and ISS III stage (HR: 1.59) at diagnosis predicted reduced OS in patients with t(11;14). These results suggest that outcomes of t(11;14) MM is inferior to other standard risk patients.Leukemia accepted article preview online, 27 June 2017. doi:10.1038/leu.2017.204.

English

Powered by Koha